Based on locations, fibromatosis is further classified into two main types, superficial and deep. The former tends to involve superficial fascia or aponeurosis, and the deep type is categorized as extraabdominal (60%), abdominal wall (25%), and intra-abdominal (desmoid tumor, 15%). 5 Multidisciplinary treatment, including surgery, radiation, and adjuvant therapy, has been applied. Among them, surgery is the essential approach, although limitation exists. 6 Firstly, intra-abdominal fibromatosis, especially in patients with familial adenomatous polyposis (FAP), often involves the bowel or mesentery root, which is nonresectable by traditional surgery. 7 Secondly, wide resection with a negative surgical margin cannot always be achieved, which yields a high rate of recurrence. 7 Thirdly, repeated surgeries inevitably lead to formidable short gut syndrome that significantly impairs quality of life.
All these post a challenge to conventional surgery.
Multivisceral transplant (MVT), as the last straw, is a potential treatment for patients with non-resectable fibromatosis that is beyond conventional surgery. Rare MVT cases have been reported, although the prognosis and predicators are largely unknown. [8] [9] [10] [11] [12] [13] This report aimed to study the survival and recurrence in a series of six patients who had conventionally non-resectable fibromatosis and underwent MVT.
| MATERIALS AND METHODS

| Patients
Six patients who underwent MVT for non-resectable intra-abdominal fibromatosis were identified in the Indiana University Health surgical pathology database from 2005 to 2015. The study was approved by the institutional review board. Organ procurement, preservation, and the procedure of MVT were followed as previously described. 14, 15 The evisceration consisted of dissection of the intra-abdominal organs including celiac and superior mesenteric artery inflow, liver, pancreaticoduodenal complex, small bowel, and part of colon. Lymph nodes in the retroperitoneum were also resected during the procedure. The cluster graft organs included stomach, small bowel, and portion of colon, liver, and pancreas. All patients received antibody-based induction immunosuppression with calcineurin-inhibitor-based maintenance and low-dose steroids, as well as protocols of graft surveillance and infectious prophylaxis. 16, 17 In comparison, 24 patients who underwent conventional surgeries for intra-abdominal fibromatosis were identified from the same time period. Patients who had abdominal wall and parietal fibromatosis were excluded from the study.
| Histomorphologic review
The cases were reviewed by two pathologists (ZC and JL) to compare the histomorphologic features. Tumor site, size and number, surgical margin status, involved organs, tumor necrosis, and mitosis were evaluated. Mitosis was assessed at a magnification of ×400 using an Olympus BX51 microscope. Representative fields were selected, and at least 500 nucleated tumor cells were assessed for each case.
| Immunohistochemical evaluation
Immunohistochemistry for assessing Ki67, p53, and β-catenin was 
| Statistics
Categorical data were compared using the χ 2 test. Continuous data were compared using Student's t test. A P value less than .05 is considered statistically significant.
| RESULTS
| Demographics
Three patients who received MVT were men (50%), and the average age of MVT group was 41 years (range, 29-60 years). Eleven patients who received conventional surgery were men (46%), and the average age was 42 years (range, 15-70 years). There was no age or gender difference in two study groups (P > .05).
Four patients in MVT group and six patients in conventional group had FAP. Two FAP patients in MVT group had an initial intestine-only transplantation before MVT, and the allografts failed. Three patients in MVT group had prior multiple small bowel resections or subtotal colectomy. These patients in MVT group presented with short gut syndrome or frozen abdomen (Table 2) . Two MVT patients (#1 and 4)
had received adjuvant therapy (tamoxifen, methotrexate, or imatinib, Table 2 ).
| Histopathologic evaluation
As shown in Table 1 , the primary site was mesentery for all patients in the study. The average size of tumor was 14.6 cm (range, 4.5-25 cm)
in MVT group compared to that of 8.5 cm (range, 1.5-26 cm) in conventional group (P = .19). The average number of tumors in MVT T A B L E 2 The clinicopathological characteristics of the 6 patients who had multivisceral transplant for intra-abdominal fibromatosis group was three (range, 1-9), which was statistically higher than that of 1.4 (range, 1-4) in conventional group (P = .0005). Three patients in MVT group had positive resection margins (50%) compared to that of 54% in conventional group. Involved organs in MVT group included small bowel (100%), stomach (33%), pancreas (33%), spleen (33%), and liver (16%), which were more extensive in contrast to those of small bowel (100%), stomach (4%), and colon (12%) in conventional group.
Necrosis was not present and mitotic figures were rare in both study groups. The clinicopathological features of each individual patient who had MVT were shown in Table 2 .
| Prognosis
As shown in Table 3 Further analysis was performed in five MVT patients respective to recurrence. As shown in Table 4 , recurrence occurred in two of three patients whose surgical margins were positive. Although there was likely a trend that positive margin was associated with recurrence, it was not statistically significant (P > .05).
| Immunohistochemistry study
Immunohistochemistry for Ki67, p53, and β-catenin was performed on the tumor tissue in MVT group (Figure 1 ; Table 4 ). In the two patients with recurrent disease, 83% (mean; range, 82%-84%) of tumor cells were positive for nuclear β-catenin immunostaining compared to 51% (mean; range, 31%-64%) in three nonrecurrent cases (P > .05).
Ki67 proliferation indexes were 4% (mean; range, 3%-5%) in recurrent cases compared with 2% (mean; range, 0%-3%) in nonrecurrent group (P > .05). p53 immunoreactivity was 5% (mean; range, 2%-8%) versus One patient died shortly after MVT due to hemorrhagic stroke. FAP, familial adenomatous polyposis; MVT, multivisceral transplant.
T A B L E 3 Follow-up and recurrence of intra-abdominal fibromatosis
MVT Recurrent Nonrecurrent
Number of patients 
| DISCUSSION
MVT was first performed 30 years ago by Dr. Starzl et al in a child with short gut syndrome and secondary liver failure. 19 Since then,
MVT has been performed around the world with varying degrees of success. Major indications for MVT in both children and adults include gastroschisis, necrotizing enterocolitis, intestinal atresia, mesenteric thrombosis, trauma, and intestinal dysmotility syndrome. 20 Recently, non-resectable intra-abdominal fibromatosis involving the mesenteric root has been indicated for MVT. However, given the complex natures of MVT and associated high risks, only a handful of studies have been published (Table 5) . [8] [9] [10] [11] [12] [13] The first MVT for intraabdominal fibromatosis was reported by Misiakos et al in 1999. short gut syndrome with extensive fibromatosis involving the pancreas and duodenum. All patients survived the procedure without recurrence. The overall cumulative survival rate was 90% at 1 year and 77% at 10 years. In 2013, Nikeghbalian et al 13 published one case.
The patient survived the procedure without recurrence. In the current report, six patients received MVT for non-resectable fibromatosis with a median follow-up of 64 months. To our knowledge, this represents the second largest series in the literature.
The overall 1-year and 5-year survival rates were both 67% for MVT patients; and the recurrence rate was 40% for the five followed up patients. In summary, 22 (88%) of 25 patients who survived MVT have been reported so far in the English literature. Among them, three (15%) had known recurrence. In comparison, the overall 1-year and 5-year survival rates were both 96% for the conventional surgery group, and the recurrence rate was 25% for the followed up patient. These results are comparable with the 1-and 5-year recurrence-free survival rates of 81.3% and 52.8% reported in Johns
Hopkins study. 21 The six patients in MVT group had multiple tumors, and the tumor load was larger extensively involving multiple visceral organs in comparison with those in conventional group. Among six MVT patients, most had prior surgeries including multiple small bowel resection (1), subtotal colectomy (2), and isolated small intestinal transplantation (2).
Among them, two patients had adjuvant therapy. But, all these treatments failed to control the tumor progression which fatally involved the mesentery root and multiple visceral organs. As noted, the largest size of the tumor in one of our patient (#3) was less than 5 cm, but this patient had four fibromatosis tumors (4.5, 4, 3.5, and 2.5 cm) involving multiple visceral organs (liver, stomach, pancreas, small bowel, and spleen) that caused short gut syndrome. Although autologous reconstruction of superior mesentery artery base, autotransplantation or ex vivo resection would be feasible for some small-size tumors, they were not suitable in this particular case, because of the extensive tumor involvement in multiple important visceral organs that made it nonresectable by conventional surgery. It is worth mentioning that MVT is truly the last straw that should be considered for fibromatosis patients when all the other possible options are excluded, given the complex nature and the high risk of the procedure.
An interesting finding of our study is that patients with FAP in MVT group had a trend of lower recurrence rate compared to their counterparts in conventional surgery, which keeps in line with Cruz's observation. 12 Although sporadic and FAP-associated fibromatosis both have enhanced β-catenin protein expression, the mechanisms are different. It is known that the characteristic APC mutation in FAP causes nuclear accumulation of β-catenin protein, while the CTNNB1 mutation leads to nuclear accumulation of β-catenin protein in sporadic fibromatosis. 22 This difference in pathogenesis might play a role in recurrence, although further investigation is warranted.
Prognostic factors for recurrence in MVT were also studied. Our data indicate that surgical margin, Ki67 proliferative index, β-catenin, and p53 expression do not significantly correlate to recurrence. Given the small size of cases, more studies from multiple transplant centers are warranted to finalize the conclusion.
In summary, MVT is a viable option for patients with advanced intra-abdominal fibromatosis who are, otherwise, ultimately fatal and not amenable to conventional options. Surgical margin, Ki67 proliferative index, β-catenin, and p53 expression are not predicative for recurrence of fibromatosis in patients who takes MVT.
